Year: 2019
Year: 2019
DOP01: Efficacy and safety of the IL-6 trans-signalling inhibitor olamkicept: a phase 2 randomized, placebo-controlled trial in moderately to severely active Ulcerative ColitisECCO'21 VirtualYear: 2021
Authors: Chen, B.(1);Zhang, S.(1);Wang, B.(2);Chen, H.(3);Li, Y.(4);Cao, Q.(5);Zhong, J.(6);Xie, M.(7);Ran, Z.(8);Tang, T.(9);Yang, M.(10);Guo, T.(10);Xu, B.(10);Cai, Z.(10);Schreiber, S.(11);Chen, M.(1);
(1)The First Affiliated Hospital of Sun Yat-sen University, gastroenterology department, Guangzhou, China;(2)Tianjin Medical University General Hospital, gastroenterology department, Tianjin, China;(3)Zhongda Hospital Affiliated to Southeast University, gastroenterology department, Nanjing, China;(4)Shengjing Hospital affiliated to China Medical University, gastroenterology department, Shenyang, China;(5)Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, gastroenterology department, Hangzhou, China;(6)Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, gastroenterology department, Shanghai, China;(7)National Taiwan University Hospital, gastroenterology department, Taibei, China;(8)Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, gastroenterology department, Shanghai, China;(9)The First Hospital of Jilin University, gastroenterology department, Changchun, China;(10)I-Mab Biopharma, Research and Development, Shanghai, China;(11)University Hospital Schleswig-Holstein, Department Medicine I, Kiel, Germany
DOP02: αEβ7 positive γδ T cells are associated with mucosal healing in Ulcerative Colitis and have a homeostatic immunophenotypeECCO'21 VirtualYear: 2021
Authors: Dart, R.(1,2);Zlatareva, I.(1,2);Irving, P.(1,3);Hayday, A.(1,2)
(1)King's College London, Peter Gorer Department of Immunobiology, London, United Kingdom;(2)Francis Crick Institute, Immunosurveillance Lab, London, United Kingdom;(3)Guy's and St Thomas Hospital, Department of Gastroenterology, London, United Kingdom
DOP03: Early change in epithelial neutrophilic infiltrate predicts long-term response to biologics in Ulcerative ColitisECCO'21 VirtualYear: 2021
Authors: Narula, N.(1);Wong, E.(1);Colombel, J.F.(2);Riddell, R.(3);Marshall, J.(4);Reinisch, W.(5);Dulai, P.(6)
(1)McMaster University, Department of Medicine- Division of Gastroenterology, Hamilton, Canada;(2)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(3)Mount Sinai Hospital, Department of Pathology and Laboratory Medicine, Toronto, Canada;(4)McMaster University, Department of Gastroenterology, Hamilton, Canada;(5)Medical University of Vienna, Department of Internal Medicine III- Division of Gastroenterology and Hepatology, Vienna, Austria;(6)University of California San Diego, Division of Gastroenterology, La Jolla, United States
DOP04: Single cell RNA sequencing identifies distinct intestinal inflammation patterns between primary sclerosing cholangitis-associated colitis and Ulcerative ColitisECCO'21 VirtualYear: 2021
Authors: Uniken Venema, W.(1);Bangma, A.(1);Van der Wijst, M.(2);Kats-Ugurlu, G.(1);Bjork, J.(1);Vich Vila, A.(1);Weersma, R.(1);Festen, E.(1)
(1)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University Medical Center Groningen, Department of Clinical Genetics, Groningen, The Netherlands
DOP05: Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative ColitisECCO'21 VirtualYear: 2021
Authors: Sandborn, W.(1);Ding, Z.(2);Osterhout, R.(2);Feagan, B.(3);Danese, S.(4);Jucov, A.(5,6);Bhandari, B.R.(7);Raghupathi, K.(8);Olson, A.(9);Van Biene, C.(8);Ford, J.(10);Aranda, R.(9);Levesque, B.G.(9);Bruey, J.M.(2)
(1)University of California San Diego, Gastroenterology, San Diego, United States;(2)Gossamer Bio- Inc., Translational Medicine, San Diego, United States;(3)Western University- Alimentiv- Inc., Gastroenterology, London, Canada;(4)Humanitas Research and Teaching Hospital, Gastroenterology, Milan, Italy;(5)ARENSIA Exploratory Medicine GmbH, Gastroenterology, Dusseldorf, Germany;(6)Nicolae Testemițanu State University of Medicine and Pharmacy, Gastroenterology, Chișinău, Moldova- Republic Of;(7)Delta Research Partners, Gastroenterology, Bastrop, United States;(8)Gossamer Bio- Inc., Biometrics, San Diego, United States;(9)Gossamer Bio- Inc., Clinical Development, San Diego, United States;(10)Gossamer Bio- Inc., Clinical Operations, San Diego, United States
DOP06: Histologic activity in Ulcerative Colitis patients achieving endoscopic healing is associated with higher rate of relapse and a distinct mucosal microbial and transcriptional profileECCO'21 VirtualYear: 2021
Authors: Hernandez-Rocha, C.(1);Turpin, W.(2);Nayeri, S.(3);Borowski, K.(3);Stempak, J.(3);Conner, J.(4);Silverberg, M.S.(1)
(1)Zane Cohen Centre for Digestive Diseases- Lunenfeld-Tanenbaum Research Institute- Sinai Health System, Division of Gastroenterology- Mount Sinai Hospital- University of Toronto, Toronto- ON, Canada;(2)Zane Cohen Centre for Digestive Diseases- Lunenfeld-Tanenbaum Research Institute- Sinai Health System, Department of Medicine- University of Toronto, Toronto- ON, Canada;(3)Zane Cohen Centre for Digestive Diseases- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto- ON, Canada;(4)Department of Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto- ON, Canada